The First Molecular Screening of MLH1 and MSH2 Genes in Moroccan Colorectal Cancer Patients Shows a Relatively High Mutational Prevalence

被引:4
作者
Zahra Moufid, Fatima [1 ,2 ]
Bouguenouch, Laila [1 ,3 ]
El Bouchikhi, Ihssane [1 ,2 ]
Chbani, Laila [3 ]
Iraqui Houssaini, Mohamed [2 ]
Sekal, Mohamed [4 ]
Belhassan, Khadija [1 ]
Bennani, Bahia [5 ]
Ouldim, Karim [1 ,3 ]
机构
[1] Ctr Hosp Hassam II, Dept Med Genet & Oncogenet, Fes, Morocco
[2] Univ Sidi Mohammed Ben Abdellah, Fac Sci & Tech, Microbial Biotechnol Lab, Fes, Morocco
[3] Univ Sidi Mohammed Ben Abdellah, Fac Med & Pharm Fes, Lab Biomed & Translat Res, Fes, Morocco
[4] Hassan II Univ Hosp, Pathol Anat & Mol Pathol Serv, Fes, Morocco
[5] Univ Sidi Mohammed Ben Abdellah, Fac Med & Pharm Fes, Genom & Oncogene Factors, Microbiol & Mol Biol Lab,Microorganisms Team, Fes, Morocco
关键词
Lynch syndrome; MLH1; MSH2; colorectal cancer; Moroccan patients; molecular screening; REVISED BETHESDA GUIDELINES; LYNCH-SYNDROME; MICROSATELLITE INSTABILITY; COST-EFFECTIVENESS; POPULATION; MANAGEMENT; DIAGNOSIS; DNA;
D O I
10.1089/gtmb.2018.0067
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Lynch syndrome (LS) is an autosomal dominant disorder characterized by early age of onset and increased risk of developing extracolonic tumors. Molecular diagnosis of LS requires identification of germline mutations in one of the Mismatch Repair (MMR) genes. Aim: The objective of the study was to investigate the prevalence of MLH1/MSH2 mutation carriers among Moroccan patients with colorectal cancer (CRC) in a hospital-based cohort. Methods: In this study, 214 CRC patients from COLORECFez cohort were included. Patients whose tumors showed MMR deficiency (MMR-D) and wild-type BRAF were selected to undergo mutational analysis of the MLH1 and MSH2 genes using Sanger sequencing. Results: A total of 24 MMR-D tumors were identified (11.2%) among 214 CRC tested for MMR protein expression. The BRAF p.Val600Glu mutation was absent in all tumors deficient for MLH1 protein. Molecular screening showed germline MMR mutations (MLH1/MSH2) in four cases, two of which fulfilled Amsterdam criteria II and two met at least one of the revised Bethesda guidelines. The estimated frequency of MLH1/MSH2 mutations in Moroccan CRC patients was 1.87%. Conclusions: The present study reports a relatively high incidence of MLH1/MSH2 (1.87%). These results confirm the contribution of MMR genes to CRC susceptibility in our population and provide evidence regarding the requirement of implementing a national screening program for LS in Morocco.
引用
收藏
页码:492 / 497
页数:6
相关论文
共 30 条
[1]   Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas [J].
Boissiere-Michot, Florence ;
Frugier, Helene ;
Ho-Pun-Cheung, Alexandre ;
Lopez-Crapez, Evelyne ;
Duffour, Jacqueline ;
Bibeau, Frederic .
VIRCHOWS ARCHIV, 2016, 469 (02) :135-144
[2]  
Chbani L, 2012, PAN AFR MED J, V13
[3]   Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan [J].
Chen, Ying-Erh ;
Kao, Sung-Shuo ;
Chung, Ren-Hua .
PLOS ONE, 2016, 11 (08)
[4]   Prevalence of Lynch syndrome and Lynch-like syndrome among patients with colorectal cancer in a Japanese hospital-based population [J].
Chika, Noriyasu ;
Eguchi, Hidetaka ;
Kumamoto, Kensuke ;
Suzuki, Okihide ;
Ishibashi, Keiichiro ;
Tachikawa, Tetsuhiko ;
Akagi, Kiwamu ;
Tamaru, Jun-Ichi ;
Okazaki, Yasushi ;
Ishida, Hideyuki .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (02) :108-117
[5]   Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis [J].
Gallego, Carlos J. ;
Shirts, Brian H. ;
Bennette, Caroline S. ;
Guzauskas, Greg ;
Amendola, Laura M. ;
Horike-Pyne, Martha ;
Hisama, Fuki M. ;
Pritchard, Colin C. ;
Grady, William M. ;
Burke, Wylie ;
Jarvik, Gail P. ;
Veenstra, David L. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) :2084-U145
[6]  
Gelband H., 2015, Cancer: Disease Control Priorities, V3
[7]   Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancere [J].
Giardiello, Francis M. ;
Allen, John I. ;
Axilbund, Jennifer E. ;
Boland, C. Richard ;
Burke, Carol A. ;
Burt, Randall W. ;
Church, James M. ;
Dominitz, Jason A. ;
Johnson, David A. ;
Kaltenbach, Tonya ;
Levin, Theodore R. ;
Lieberman, David A. ;
Robertson, Douglas J. ;
Syngal, Sapna ;
Rex, Douglas K. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 (08) :1159-1179
[8]   Interactions of human hMSH2 with hMSH3 and hMSH2 with hMSH6: Examination of mutations found in hereditary nonpolyposis colorectal cancer [J].
Guerrette, S ;
Wilson, T ;
Gradia, S ;
Fishel, R .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (11) :6616-6623
[9]   Screening for the Lynch syndrome (Hereditary nonpolyposis colorectal cancer). [J].
Hampel, H ;
Frankel, WL ;
Martin, E ;
Arnold, M ;
Khanduja, K ;
Kuebler, P ;
Nakagawa, H ;
Sotamaa, K ;
Prior, TW ;
Westman, J ;
Panescu, J ;
Fix, D ;
Lockman, J ;
Comeras, I ;
de la Chapelle, A ;
Ellison, C ;
Melvin, S ;
Winston, J ;
Adeli, A ;
Burak, W ;
Chadwick, R ;
Elkhatib, I ;
Hemingway, T ;
Jamieson, K ;
Johnson, C ;
LaJeunesse, J ;
Liyanarachchi, S ;
Rangel, P ;
Soble, D ;
Walker, M ;
Wise, T ;
Zhang, Y ;
Schlanger, R ;
Aguilar, P ;
Hura, D ;
Keith, J ;
Kerner, B ;
Lavalle, G ;
Taylor, C ;
Vara, T ;
Zangmeister, J ;
DeVictor, S ;
Hines, L ;
Lindsey, M ;
Madhavan, J ;
Padmanabhan, A ;
Hamelberg, K ;
Niemann, T ;
Behrens, BC ;
Blair, SC .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (18) :1851-1860
[10]   Selective Versus Universal Screening for Lynch Syndrome: A Six-Year Clinical Experience [J].
Kidambi, Trilokesh D. ;
Blanco, Amie ;
Myers, Megan ;
Conrad, Peggy ;
Loranger, Kate ;
Terdiman, Jonathan P. .
DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (08) :2463-2469